Lu Tian

发表

Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes.

H. Uno, M. Pfeffer, Lee-Jen Wei, 2022, NEJM evidence.

Fulvestrant plus capivasertib for metastatic breast cancer.

Lee-Jen Wei, Z. McCaw, D. H. Kim, 2020, The Lancet. Oncology.

Trifluridine/tipiracil in metastatic gastric cancer.

Lee-Jen Wei, H. Fu, Z. McCaw, 2019, The Lancet. Oncology.

Evaluating Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma.

Lee-Jen Wei, R. Sun, Lu Tian, 2022, JAMA surgery.

Sex as a predictor of response to cancer immunotherapy.

Lee-Jen Wei, M. Takeuchi, Z. McCaw, 2018, The Lancet. Oncology.

Quantifying the Effect of Lower vs Higher Positive End-Expiratory Pressure on Ventilator-Free Survival in ICU Patients.

Lee-Jen Wei, Z. McCaw, Lu Tian, 2021, JAMA.

Predictive signature development based on maximizing the area between receiver operating characteristic curves

V. Devanarayan, Saptarshi Chatterjee, Xin Huang, 2022, Statistics in medicine.

Handling Informative Premature Treatment or Study Discontinuation for Assessing Between-Group Differences in a Comparative Oncology Trial.

Lee-Jen Wei, B. Claggett, E. Ludmir, 2022, JAMA oncology.

A Composite Endpoint for Treatment Benefit According to Patient Preference

Jiying Zou, Shiyan Yan, J. Tamaresis, 2022, Statistics in Biopharmaceutical Research.

The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis

M. Pfeffer, Lee-Jen Wei, B. Claggett, 2017, Statistics in Biosciences.

Practical Recommendations on Quantifying and Interpreting Treatment Effects in the Presence of Terminal Competing Risks: A Review.

S. Solomon, M. Pfeffer, Lee-Jen Wei, 2021, JAMA cardiology.

Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies

G. Fitzmaurice, Lee-Jen Wei, F. Bretz, 2021, Statistics in medicine.

Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC).

Lee-Jen Wei, Z. McCaw, D. H. Kim, 2018, Annals of surgery.

On assessing survival benefit of immunotherapy using long‐term restricted mean survival time

H. Uno, M. Horiguchi, Lu Tian, 2023, Statistics in medicine.

Appropriate Analysis of Duration of Response Data in Cancer Trials.

Lee-Jen Wei, Z. McCaw, Lu Tian, 2020, JAMA Oncology.

Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments

Bo Huang, Lu Tian, 2022, Pharmaceutical statistics.

Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study

H. Uno, Lee-Jen Wei, F. Hong, 2021, Journal for ImmunoTherapy of Cancer.

Assessment of Median and Mean Survival Time in Cancer Clinical Trials

T. Meirson, Z. McCaw, E. Ludmir, 2023, JAMA network open.

XRRmeta: Exact Inference for Random-Effects Meta-Analyses with Rare Events (preprint)

J. Gronsbell, Z. McCaw, Lu Tian, 2023, 2306.11907.

Evaluating subject-level incremental values of new markers for risk classification rule

Lee-Jen Wei, L. J. Wei, L. Tian, 2013, Lifetime data analysis.

Moving beyond the conventional stratified analysis to estimate an overall treatment efficacy with the data from a comparative randomized clinical study

L. Tian, H. Uno, M. Pfeffer, 2018, Statistics in medicine.

Calibrating parametric subject-specific risk estimation.

Hajime Uno, T Cai, H. Uno, 2010, Biometrika.